Xenon of­fers $300M in shares af­ter tout­ing path ahead for MDD pro­gram de­spite PhII miss

Xenon Phar­ma­ceu­ti­cals has an­nounced a pub­lic of­fer­ing of $300 mil­lion in shares just days af­ter it un­veiled mixed Phase II da­ta for its ma­jor de­pres­sive dis­or­der pro­gram.

Al­though the can­di­date failed the study’s pri­ma­ry end­point, the com­pa­ny — and an­a­lysts — were bull­ish about its path for­ward giv­en its pos­i­tive safe­ty pro­file and sec­ondary end­point da­ta.

The pub­lic of­fer­ing is ex­pect­ed to close on Dec. 4, Xenon said in a com­pa­ny press re­lease on Wednes­day night. The Cana­di­an biotech end­ed Sep­tem­ber with a cash po­si­tion of $639.1 mil­lion, which it said would sup­port two Phase III stud­ies of its MDD can­di­date XEN1101 in two oth­er in­di­ca­tions of fo­cal on­set and pri­ma­ry gen­er­al­ized ton­ic-clonic seizures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER